#ACXP

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update Acurx Pharmaceuticals (NASDAQ: ACXP) reported full-year 2025 results and a business update on March 13, 2026. Key items: cash $7.6M, gross equity-line proceeds ~$4.0M in 2025, net loss $8.0M for 2025, and 2,348,113 shares outstanding.Clinical highlights include a planned open-label 20-patient rCDI pilot, Phase 2 ibezapolstat results (96% clinical cure of 26 patients, no recurrence), a new USPTO patent to Dec 2039, and structural biology publication supporting the Pol IIIC inhibitor program.

2 days ago

#ACXP Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

www.stocktitan.net/news/ACXP/acurx-pharmace...

0 0 0 0

tickerade

@tickerade.bsky.social

3 days ago

$ACXP surges +69.4% after crossing Oracle's long signal, reaching new high with +76% gain from signal.

1 0 0 0

Acurx Pharma (Nasdaq: ACXP) awarded $375K Health~Holland grant for Pol IIIC MRSA work Health~Holland grants approx. $375,000 to LUMC and Acurx to advance Pol IIIC inhibitor studies, first MRSA PolC 3D structure, and Phase 3-ready ibezapolstat.

3 months ago

#ACXP Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

www.stocktitan.net/news/ACXP/health-holland...

0 0 0 0

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update STATEN ISLAND, N.Y., Nov. 12, 2025/ PRNewswire/-- Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.. On August 4, 2025, we effected a 1- for-20 reverse...

4 months ago

#ACXP Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

www.stocktitan.net/news/ACXP/acurx-pharmace...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Leading Indicators, Monday November 10, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Mon Nov 10th - #ENTO #ACON #MLKN #ENTX #ACXP #RGR #GWH #FFWM - More: crystalequityresearch.com/leading-indi... - #smallcap

1 0 0 0

4 months ago

#ACXP Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

www.stocktitan.net/news/ACXP/acurx-announce...

0 0 0 0

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update Acurx Pharmaceuticals (NASDAQ: ACXP) will discuss its third quarter 2025 financial results on Wednesday, November 12, 2025 at 8:00 a.m. ET before U.S. markets open.David P. Luci, President and CEO, and Robert G. Shawah, CFO, will host a conference call to review the results and provide a business update. Toll-free U.S. dial-in is 1-877-790-1503 with Conference ID 13756868; international participant numbers are available via the company’s conferencing link.

4 months ago

#ACXP Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

www.stocktitan.net/news/ACXP/acurx-pharmace...

0 0 0 0

Giants67

@giants1967.bsky.social

5 months ago

Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC ACCESS Newswire is the leading global press release distribution service. Tell your story and reach millions of journalists. Contact us today to get started.

Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC
www.accessnewswire.com/newsroom/en/...
#SNYR #RDZN #ACXP

0 0 0 0

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors Acurx (NASDAQ: ACXP) announced an Australian patent grant for DNA Polymerase IIIC inhibitors, adding to its global intellectual property that already includes three U.S. patents and patents in Israel, Japan and India.The patent covers compositions of matter tied to the ACX-375C program. Management noted the lead DNA pol IIIC inhibitor is Phase 3-ready for oral C. difficile treatment, while new preclinical compounds are systemically absorbed for potential oral and parenteral use across indications including ABSSSI (MRSA), CABP, HABP/VABP, bacteremia/sepsis, endocarditis, bone/joint infections, prosthetic joint infections and inhalational anthrax.

5 months ago

#ACXP Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

www.stocktitan.net/news/ACXP/australian-pat...

0 0 0 0

20,000 Children Affected Annually: Acurx's New Antibiotic Gets Key EMA Support for C. difficile Treatment Acurx's ibezapolstat receives EMA PDCO positive opinion for pediatric C. difficile treatment. Drug targets 20,000 annual child cases, with potential for 11-year EU exclusivity.

5 months ago

#ACXP Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

www.stocktitan.net/news/ACXP/acurx-announce...

0 0 0 0

Biotech Acurx Pharmaceuticals Secures Future on Nasdaq by Meeting Critical $1 Bid, $2.5M Equity Rules Late-stage biotech Acurx Pharmaceuticals (ACXP) confirms full compliance with Nasdaq listing requirements, meeting minimum $1.00 bid price and $2.5M stockholders' equity thresholds.

6 months ago

#ACXP Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

www.stocktitan.net/news/ACXP/acurx-pharmace...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Trade Alerts, Wednesday August 13, 2025 – Crystal Equity Research

Small-cap stocks oversold with improving relative strength, Wed Aug 13th - #CYCA #MURA #LGVN #IBIO #HRTX #FNKO #FAT #ACXP #TIC #FVRR - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Acurx Earnings: Net Loss Slashed by Half as Phase 2b Data Published in Lancet Microbe Acurx reports 46% smaller Q2 loss, strengthens cash position, and achieves key clinical milestones. Phase 2b trial results published in Lancet Microbe. See details.

7 months ago

#ACXP Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

www.stocktitan.net/news/ACXP/acurx-pharmace...

0 0 0 0

Acurx Pharmaceuticals Plans Major 1:20 Reverse Split - Key Details for Nasdaq Compliance Acurx shares to consolidate 1:20 starting August 5, reducing outstanding shares from 30.7M to 1.5M. Learn how this affects your holdings.

7 months ago

#ACXP Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

www.stocktitan.net/news/ACXP/acurx-pharmace...

0 0 0 0

Acurx Pharmaceuticals Earnings: Antibiotic Developer to Reveal Q2 2025 Results and Pipeline Progress Clinical-stage biotech Acurx to discuss latest financial performance and provide updates on their novel antibiotics pipeline. Join the conference call.

7 months ago

#ACXP Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

www.stocktitan.net/news/ACXP/acurx-pharmace...

0 0 0 0

8 months ago

🚀 Exciting times for #ACXP! With bullish momentum and a positive MACD, there's potential for upward movement. Consider entering at $0.58, targeting $0.62 & $0.65. But stay sharp—geopolitical tensions could impact gains. Risk management is key! 📈 #FeetrAI #StockWatch

0 0 0 0

8 months ago

🚀 Exciting times for #ACXP! Trading at $0.591, with a slightly bullish vibe. RSI at 56.18 shows room to grow, and MACD hints at positive momentum. Eyes on the FDA decision for their new antibiotic—could be a game-changer! 🎯 Target: $0.65-$0.70. Stay tuned! 📈 #Stocks #Biotech

0 0 0 0

8 months ago

🚀 Exciting times for #ACXP! Trading at $0.591, this biotech gem is on the radar with a pivotal FDA decision looming. Bullish momentum spotted with an 8-day EMA of $0.513 and MACD divergence. Speculative play? Enter at $0.59, target $0.70-$0.80, stop loss $0.55. 📈 #FeetrAI

0 0 0 0

8 months ago

🚀 Exciting times for #ACXP! With a surge in trading volume and bullish technicals, Acurx Pharmaceuticals is on the move. Entry at $0.60 looks promising, targeting $0.65 & $0.68. Keep an eye on market shifts and set your stop loss at $0.58. 📈 #FeetrAI #StockWatch

0 0 0 0

8 months ago

🚀 Exciting times for #ACXP! Trading at $0.6815, it's showing bullish momentum with a high RSI. Consider a cautious long position if it holds above $0.68. Target: $0.75 & $0.80, stop loss at $0.65. Stay alert for news! 📈 #FeetrAI #StockWatch

0 0 0 0

8 months ago

🚀 Exciting times for #ACXP! With high trading volume and technical breakouts, this stock is on the move. RSI over 70 signals overbought, but MACD shows bullish momentum. Consider a long position at $0.68, targeting $0.75 & $0.80. Stay alert for news! 📈 #FeetrAI

0 0 0 0

8 months ago

🚀 Exciting times for #ACXP! With a price surge from $0.30 to $0.78, high volume, and bullish momentum, this stock is on fire! 🔥 RSI over 70 signals overbought, but technicals suggest a LONG play. Entry: $0.68, Targets: $0.75/$0.80, Stop: $0.65. Stay alert! 📈 #FeetrAI

0 0 0 0

Acurx Pharmaceuticals Raises Fresh $2.67M Capital: New Antibiotic Development Gets Major Funding Boost Late-stage biotech secures crucial funding for novel antibiotics program. New warrant structure offers potential for additional capital raise. See detailed terms.

8 months ago

#ACXP Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

www.stocktitan.net/news/ACXP/acurx-pharmace...

0 0 0 0

8 months ago

🚀 Exciting times for #ACXP! With FDA approval boosting interest, trading volume is soaring. RSI suggests overbought, but MACD shows positive momentum. Consider a long position at $0.72, targeting $0.85 & $1.00. Stay sharp—volatility is high! 📈 #FeetrAI #StockWatch

0 0 0 0

Market Wire News

@marketwirenews.com

8 months ago

Breaking News: ( NASDAQ: #ACXP ) Acurx Publishes Promising Phase 2b CDI Trial Data for Ibezapolstat in Lancet Microbe

0 0 0 0

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI Acurx Pharmaceuticals (NASDAQ: ACXP) announced the publication of Phase 2b clinical trial results for ibezapolstat (IBZ) in Lancet Microbe, showing superior efficacy in treating C. difficile infection (CDI) compared to standard treatment. The trial demonstrated 94% clinical cure rate with IBZ, with 100% of cured patients remaining recurrence-free after one month, versus 14% recurrence rate with vancomycin. IBZ also showed favorable effects on gut microbiome preservation. The drug has received FDA QIDP and Fast-Track Designation, plus EMA SME status. The company is now positioned to advance to Phase 3 international trials, supported by comprehensive data including chemistry, mechanism of action, and microbiological activity. This development is particularly significant as current treatments show lower cure rates and emerging antimicrobial resistance issues.

8 months ago

#ACXP Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

www.stocktitan.net/news/ACXP/acurx-announce...

0 0 0 0